ES2748864T3 - Proteínas ENV lentivíricas mutadas y su uso como fármacos - Google Patents

Proteínas ENV lentivíricas mutadas y su uso como fármacos Download PDF

Info

Publication number
ES2748864T3
ES2748864T3 ES12806388T ES12806388T ES2748864T3 ES 2748864 T3 ES2748864 T3 ES 2748864T3 ES 12806388 T ES12806388 T ES 12806388T ES 12806388 T ES12806388 T ES 12806388T ES 2748864 T3 ES2748864 T3 ES 2748864T3
Authority
ES
Spain
Prior art keywords
protein
mutated
seq
env
fragment
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
ES12806388T
Other languages
English (en)
Spanish (es)
Inventor
Thierry Heidmann
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Centre National de la Recherche Scientifique
Institut Gustave Roussy
Université Paris-Sud
Viroxis SAS
Original Assignee
Centre National de la Recherche Scientifique
Institut Gustave Roussy
Université Paris-Sud
Viroxis SAS
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Centre National de la Recherche Scientifique, Institut Gustave Roussy, Université Paris-Sud, Viroxis SAS filed Critical Centre National de la Recherche Scientifique
Application granted granted Critical
Publication of ES2748864T3 publication Critical patent/ES2748864T3/es
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/21—Retroviridae, e.g. equine infectious anemia virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/15011—Lentivirus, not HIV, e.g. FIV, SIV
    • C12N2740/15022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/15011—Lentivirus, not HIV, e.g. FIV, SIV
    • C12N2740/15034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16111—Human Immunodeficiency Virus, HIV concerning HIV env
    • C12N2740/16122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16111—Human Immunodeficiency Virus, HIV concerning HIV env
    • C12N2740/16134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Molecular Biology (AREA)
  • Communicable Diseases (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Hematology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oncology (AREA)
  • Engineering & Computer Science (AREA)
  • AIDS & HIV (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
ES12806388T 2011-12-07 2012-12-07 Proteínas ENV lentivíricas mutadas y su uso como fármacos Active ES2748864T3 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP11306625 2011-12-07
PCT/EP2012/074835 WO2013083799A1 (en) 2011-12-07 2012-12-07 Mutated lentiviral env proteins and their use as drugs

Publications (1)

Publication Number Publication Date
ES2748864T3 true ES2748864T3 (es) 2020-03-18

Family

ID=47435901

Family Applications (1)

Application Number Title Priority Date Filing Date
ES12806388T Active ES2748864T3 (es) 2011-12-07 2012-12-07 Proteínas ENV lentivíricas mutadas y su uso como fármacos

Country Status (16)

Country Link
US (1) US9682137B2 (enExample)
EP (1) EP2788372B1 (enExample)
JP (2) JP6415324B2 (enExample)
KR (1) KR102059918B1 (enExample)
CN (1) CN104169295B (enExample)
AU (1) AU2012350258B2 (enExample)
BR (1) BR112014013704B1 (enExample)
CA (1) CA2856180C (enExample)
DK (1) DK2788372T3 (enExample)
ES (1) ES2748864T3 (enExample)
IL (1) IL232926B (enExample)
IN (1) IN2014CN04927A (enExample)
MX (1) MX350689B (enExample)
RU (1) RU2654673C2 (enExample)
WO (1) WO2013083799A1 (enExample)
ZA (1) ZA201403617B (enExample)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11351247B2 (en) * 2017-09-01 2022-06-07 Inprother Aps Vaccine for use in the prophylaxis and/or treatment of a disease
CN117500931A (zh) * 2021-01-13 2024-02-02 维洛克塞斯 麻疹-hiv或麻疹-htlv疫苗
US20240093233A1 (en) 2021-01-13 2024-03-21 Viroxis Measles-hiv or measles-htlv vaccine

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1201750A1 (en) * 2000-10-26 2002-05-02 Genopoietic Synthetic viruses and uses thereof
WO2005012502A2 (en) 2003-03-28 2005-02-10 Idm Pharma, Inc. Methods of identifying optimal variants of peptide epitopes
AU2005229411B2 (en) * 2004-03-30 2010-11-18 Centre National De La Recherche Scientifique Polypeptide sequence involved in the modulation of the immunosuppressive effect of viral proteins
EP2420248A1 (en) 2004-08-17 2012-02-22 Institut Gustave Roussy Mutated HIV NEF for modulating immunity
CA2735278A1 (en) 2008-08-28 2010-03-04 Aarhus Universitet Hiv-1 envelope polypeptides for hiv vaccine
RU2426788C1 (ru) * 2010-03-01 2011-08-20 Федеральное государственное учреждение науки "Центральный научно-исследовательский институт эпидемиологии" Федеральной службы по надзору в сфере защиты прав потребителей и благополучия человека (ФГУН ЦНИИЭ Роспотребнадзора) Генетические конструкции для антивич-терапии

Also Published As

Publication number Publication date
DK2788372T3 (da) 2019-10-14
RU2654673C2 (ru) 2018-05-21
JP2018150370A (ja) 2018-09-27
AU2012350258B2 (en) 2017-03-02
RU2014127521A (ru) 2016-02-10
IN2014CN04927A (enExample) 2015-09-18
EP2788372A1 (en) 2014-10-15
EP2788372B1 (en) 2019-07-10
AU2012350258A8 (en) 2014-07-17
US9682137B2 (en) 2017-06-20
IL232926A0 (en) 2014-07-31
CN104169295B (zh) 2020-07-28
BR112014013704B1 (pt) 2023-01-31
CA2856180C (en) 2022-09-06
MX2014006744A (es) 2014-12-08
JP2015505836A (ja) 2015-02-26
KR102059918B1 (ko) 2020-02-11
MX350689B (es) 2017-09-13
BR112014013704A2 (pt) 2021-02-17
AU2012350258A1 (en) 2014-06-05
CN104169295A (zh) 2014-11-26
WO2013083799A1 (en) 2013-06-13
IL232926B (en) 2019-01-31
CA2856180A1 (en) 2013-06-13
ZA201403617B (en) 2015-07-29
US20140294880A1 (en) 2014-10-02
JP6415324B2 (ja) 2018-10-31
KR20140116091A (ko) 2014-10-01

Similar Documents

Publication Publication Date Title
ES2341429T3 (es) Mejoras en las respuestas inmunitarias al vih o relacionadas con las mismas.
US10946090B2 (en) Consensus/ancestral immunogens
AU2018283811B2 (en) Poxvirus vectors encoding HIV antigens, and methods of use thereof
JPH09508622A (ja) Ｄｎａ転写ユニットの接種による免疫化
PL188641B1 (pl) Szczepionka polienv przeciwko HIV, sposób wytwarzania szczepionki polienv,zastosowanie szczepionki polienv,zastosowanie przynajmniej jednego rekombinowanego białka env HIV lub przynajmniej jednego wektora DNA, który koduje ekspresję rekombinowanego białka env HIV, plazmid bifunkcjonalny.
US8048431B2 (en) Modified HIV-1 clade C envelope glycoprotein immunogens comprising deletions in the gp120/gp41 cleavage site and gp41 fusion domain
JP2018150370A (ja) レンチウイルスの変異ｅｎｖタンパク質及び薬物としてのその使用
US20140227311A1 (en) Method for Removing Immunosuppressive Properties of HIV Envelope Glycoproteins
WO2015009946A1 (en) Method of increasing immune response to hiv antigens
JP2024502658A (ja) 麻疹－ｈｉｖ又は麻疹－ｈｔｌｖワクチン
EP3004143B1 (en) Mutated non-primate lentiviral env proteins and their use as drugs
US9636396B2 (en) Mutant human and simian immunodeficiency virus ENV proteins with reduced immunosuppressive properties
ZA200204260B (en) Improvements in or relating to immune responses to HIV.